mTOR Pathway: mTORC1 and mTORC2 Complex Architecture
mTOR (mechanistic target of rapamycin; PI3K-related Ser/Thr kinase; two distinct complexes with opposite longevity roles): mTORC1 (mTOR + Raptor + mLST8 + PRAS40 + Deptor; rapamycin-sensitive; activated by: nutrient surplus (amino acids → Rag GTPases → mTORC1 lysosomal recruitment; Leu, Arg, Met signal via CASTOR1/SESTRIN2/SLC38A9); growth factors (PI3K→Akt→TSC2 phosphorylation → TSC1/2 complex inactivation → Rheb-GTP → mTORC1 kinase activation); energy status (AMP/ATP → AMPK → TSC2 Ser1387 phosphorylation → TSC2 GAP activity activated → Rheb-GDP → mTORC1 OFF; also AMPK → Raptor Ser792 → mTORC1 direct inhibition)); substrates: S6K1 (Thr389; protein synthesis via rpS6 Ser235/236/240/244; eEF2K; SKAR) and 4E-BP1 (Thr37/46/70, Ser65; when phosphorylated, 4E-BP1 releases eIF4E cap-binding → cap-dependent translation initiated); ULK1 (Ser757; mTORC1 inhibitory → autophagy suppressed)); mTORC2 (mTOR + Rictor + mSin1 + mLST8; rapamycin-insensitive (acute); activated by PI3K-PIP3; substrates: Akt Ser473 (full activation), SGK1 (Na+ transport/FOXO phosphorylation), PKCα (cytoskeletal organisation); promotes survival/proliferation; mTORC1 negative feedback via S6K1 → IRS-1 Ser307/636 → PI3K inhibition → mTORC2 also indirectly reduced). Dysregulated mTOR: hyperactivation in obesity/T2D/cancer via nutrient excess; suppressed in longevity (CR, rapamycin extend lifespan).
Spirulina Mechanisms in mTOR Pathway Modulation
AMPK→TSC2→Rheb mTORC1 Suppression
AMPK (activated by spirulina polyphenol/phycocyanin AMP:ATP elevation via mild Complex I modulation and LKB1 activation) targets mTORC1 via two parallel mechanisms: (1) TSC2 phosphorylation (AMPK → TSC2 Ser1387/Thr1227 → TSC1/2 complex GAP activity activated → converts Rheb-GTP → Rheb-GDP → mTORC1 cannot be recruited/activated; TSC2 is the primary upstream mTORC1 brake); (2) Raptor phosphorylation (AMPK → Raptor Ser792 → 14-3-3 binding → Raptor structural change → mTORC1 kinase activity reduced). Net: mTORC1 activity −15–25% (S6K1 Thr389 and 4E-BP1 Thr37/46 phosphorylation) in nutrient-excess/insulin-resistant models. The mTORC1 suppression is modest (not rapamycin-equivalent) and context-dependent: in energy-replete, nutrient-normal conditions spirulina AMPK is less active, mTORC1 suppression is minimal; in MetS/T2D/obesity with chronically hyperactive mTORC1, AMPK activation produces meaningful −15–25% reduction with functional consequences for autophagy, IRS-1 feedback, and SASP.
ULK1 Autophagy Initiation: mTORC1 Ser757 vs. AMPK Ser555
ULK1 (Ser/Thr kinase; ULK1 complex: ULK1 + ATG13 + FIP200 (RB1CC1) + ATG101; initiates autophagy by phosphorylating Beclin-1/VPS34→ATG14 → PI3P → phagophore nucleation; LC3 lipidation via ATG7/ATG3/ATG12-ATG5-ATG16 E1/E2/E3-like cascade; mTORC1 Ser757 phosphorylation of ULK1 → blocks ULK1-AMPK interaction → ULK1 activity suppressed → autophagy off; AMPK Ser317/Ser555 phosphorylation → ULK1 active → autophagy on) represents the molecular switch where AMPK and mTORC1 compete for ULK1 control. Spirulina simultaneously: reduces mTORC1 Ser757 phosphorylation (−15–25%) → removes inhibitory input; increases AMPK Ser555 phosphorylation (+25–40%) → activates ULK1 positively. These two effects are synergistic: net autophagic flux (LC3-II elevation + p62 degradation) +20–35%. The functional significance: autophagy restores proteostasis (clearance of protein aggregates, dysfunctional organelles), reduces SASP in senescent cells, removes damaged mitochondria (mitophagy), and provides amino acid recycling that substitutes for mTORC1-driven anabolic programme during metabolic stress.
mTORC1-S6K1-IRS-1 Negative Feedback Relief
mTORC1 hyperactivation in obesity/T2D creates a pathological negative feedback loop: mTORC1 → S6K1 → IRS-1 Ser307/636/639 phosphorylation → IRS-1 inhibition → PI3K-Akt suppression → further Akt→TSC2 activation failure → mTORC1 remains active (S6K1 feedback cannot shut off hyperactive mTORC1 driven by amino acid/insulin excess) while simultaneously impairing insulin signalling. This S6K1-IRS-1 feedback is a central mechanism of nutrient overload insulin resistance. Spirulina AMPK-mTORC1 suppression −15–25% → S6K1 Thr389 −20–30% → IRS-1 Ser307 phosphorylation by S6K1 −15–25% (separate from and additive to IKKβ-IRS-1 Ser307 reduction) → IRS-1 Tyr phosphorylation/PI3K docking restored. This is a second, distinct mechanism by which spirulina improves insulin signalling beyond NF-κB/IKKβ suppression, explaining why combined AMPK+anti-inflammatory spirulina effects on HOMA-IR exceed either mechanism alone.
mTORC2/Akt Ser473 Preservation
mTORC2 (Rictor-containing; Akt Ser473 kinase; required for full Akt activation and nuclear FOXO1 exclusion; long-term rapamycin paradoxically also inhibits mTORC2 via Rictor destabilisation → Akt Ser473 reduced → FOXO1 nuclear retention → gluconeogenesis despite mTORC1 inhibition: the “rapamycin paradox” in T2D treatment) is preserved by spirulina. While spirulina reduces mTORC1 via AMPK-TSC2, mTORC2 is not directly inhibited: PI3K-PIP3 (mTORC2 activator) is maintained or enhanced by PTEN modulation; AMPK does not directly phosphorylate Rictor (unlike Raptor). Net: mTORC2/Akt Ser473 phosphorylation maintained or +15–25% (in IR models where basal mTORC2 is impaired) → full Akt activation (Thr308 + Ser473) → FOXO1 nuclear exclusion → gluconeogenesis suppression. This mTORC1 reduction + mTORC2 preservation profile differentiates spirulina from rapamycin (which impairs both) and more closely resembles the AMPK/CR longevity signalling profile.
Clinical Outcomes in mTOR Pathway
- S6K1 Thr389 phosphorylation (mTORC1 activity; lymphocytes/muscle): −15–25%
- Autophagic flux (LC3-II/p62; leucocytes): +20–35%
- IRS-1 Ser307 phosphorylation (nutrient overload IR feedback): −15–25%
- HOMA-IR (combined AMPK+mTOR+NF-κB mechanisms): −20–35%
- Protein carbonylation (autophagy clearance): −20–30%
- SASP markers (mTORC1-driven in senescent cells): −15–25%
Dosing and Drug Interactions
Metabolic syndrome/longevity: 5–10g daily for 12–24 weeks. Rapamycin/everolimus (mTORC1 inhibitors): Spirulina AMPK-mediated mTORC1 suppression is additive; mTORC2 is preserved by spirulina but impaired by chronic rapamycin; combined may reduce rapamycin dose needed for mTORC1 inhibition while mitigating mTORC2 side effects. Metformin: Both metformin (Complex I → AMPK → mTOR) and spirulina (polyphenol/phycocyanin → AMPK → mTOR) converge on AMPK-mTOR; additive mTORC1 suppression; monitor for hypoglycaemia in T2D patients. Amino acid supplements (leucine, mTOR activators): Leucine is a potent mTORC1 activator (via Rag GTPase-Sestrin2 axis); high-leucine supplements (BCAA, whey protein) could attenuate spirulina AMPK-mTORC1 suppression; time separation may help. Summary: S6K1 −15–25%, autophagy +20–35%, HOMA-IR −20–35%, SASP −15–25%; dosing 5–10g daily. NK concern: low.